CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The CCTG Annual Spring Meeting is only 7 weeks away!
The CCTG IND Program has launched the Early Clinical Trials Educational Series, a virtual education workshop series that offers topics of relevance and interest to early drug trial investigation.
We are getting closer to the 2022 Virtual CCTG Annual Spring Meeting of Participants which will be held from April 28 - May 01, 2022!
Louise joined the CCTG Patient Representative Committee last year and is supporting the Melanoma & Quality of Life Committees. She is a married mother of five and Nana to 11 who enjoys spending time with her family, gardening and reading. Louise’s background is in Education and has participated as a Patient Partner in many groups and projects on both a National and Provincial level.
"I hope to improve the Patient experience and to encourage cancer patients to be involved in clinical trials and help foster change to improve the future of treatments," says Louise
The main purpose of this job is to provide electronic clinical database management from collection and entry to statistical analysis and reporting of data.
The Canadian Cancer Trials Group (CCTG) is very excited to announce that we are now accepting applications for the 2022-2023 New Investigator Cancer Trials Practicum. This is a unique opportunity for new investigators to access hands on training and practical work in the field of cancer clinical trials.The purpose of the CCTG New-Investigator Cancer Trials Practicum is to deliver a training program that includes practical trial experience at cancer sites across the country over a one-year period.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
